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Abstract: The potential role of human leukocyte antigen (HLA)-G as a target for new cancer
immunotherapy drugs has increased the interest in the analysis of mechanisms by which HLA-G
expression is regulated, and how the expression can be manipulated. We characterized HLA expression
in breast cancer and malignant melanoma cell lines and investigated the induction of HLA-G expression
by two distinct mechanisms: stimulation with interferon (IFN)-γ or inhibition of methylation by
treatment with 5-aza-2’-deoxycytidine (5-aza-dC). The effect of IFN-γ and 5-aza-dC on HLA expression
was dependent on the cancer cell lines studied. However, in general, surface expression of HLA class
Ia was induced on all cell lines. Surface expression of HLA-G was inconclusive but induction of
HLA-G mRNA was prevalent upon treatment with 5-aza-dC and a combination of IFN-γ and 5-aza-dC.
IFN-γ alone failed to induce HLA-G expression in the HLA-G-negative cell lines. The results support
that HLA-G expression is regulated partly by DNA methylation. Furthermore, IFN-γ may play a role
in the maintenance of HLA-G expression rather than inducing expression. The study demonstrates
the feasibility of manipulating HLA expression and contributes to the exploration of mechanisms
that can be potential targets for immunotherapy in breast cancer and malignant melanoma.
Keywords: HLA-G; breast cancer; malignant melanoma; in vitro modification; DNA
methylation; immunoediting
1. Introduction
The assembly of immune responses is highly dependent on human leukocyte antigen (HLA)
molecules. The HLA molecules are encoded in the human major histocompatibility complex (MHC)
and mediate immune activation and immune suppression through HLA class Ia and class Ib molecules,
respectively. The extent of immune regulation is inevitable in the context of cancer development and
treatment and so is the role of HLA-mediated interaction between tumor and immune cells. Progression
of cancer is often associated with altered expression of HLA molecules and multiple studies support
that upregulation of HLA class Ib expression, especially HLA-G, is a mechanism, whereby tumors are
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able to escape immunological surveillance [1]. A concomitant loss or downregulation of HLA class Ia
molecules can further enhance the ability of cancer cells to escape T cell recognition [2].
The highly polymorphic HLA class Ia genes, HLA-A, -B, and -C, are expressed on almost all nucleated
cells. Whereas HLA class Ib mRNA expression is frequent in many tissues, surface expression is
restricted in healthy tissue. Expression of HLA-G is mainly restricted to the trophoblast cells in the
placenta, where it participates in maintaining tolerance at the fetal-maternal interface [3,4]. However,
HLA-G expression is often induced in pathological settings and is frequently seen in various cancers [5].
Of the HLA class Ib molecules, HLA-G is probably the most studied in terms of cancer immunology
and the most well-defined immunosuppressive molecule of the HLAs favoring tumor immune escape.
Whereas knowledge of the role of HLA-F in cancer is sparse, HLA-E expression is also seen in several
cases of cancers associated with immune suppression.
We have previously shown an association between high HLA-G and HLA-ABC expression
with tumor aggressiveness and a worse prognosis in a study including 250 malignant melanoma
patients [6]. Furthermore, HLA-G might serve as a prognostic marker in combination with HLA-E [7].
Expression of HLA-E is correlated with reduced immunogenicity in renal cell carcinoma [8], and in
non-small cell lung carcinoma HLA-E expression is suggested to restrain the positive prognostic
effect of infiltrating cytotoxic T cells [9]. A concomitant loss of HLA class Ia and high expression of
HLA-G and HLA-E is associated with a worse prognosis and increased metastatic capacity in breast
cancer [10–12]. Furthermore, both HLA-G and HLA-E expression are correlated with poor survival
and tumor metastasis in colorectal cancer [13,14]. Interestingly, different HLA-G isoforms seem to
differentially increase the surface expression of HLA-E [15].
HLA-G exist in seven well-recognized isoforms. HLA-G1 to -G4 are membrane-bound molecules
and HLA-G5- to -G7 are soluble proteins due to alternative splicing and skipping of different
exons [16–19]. Expression of the different isoforms might have different functional implications and
even though the expression pattern of the HLA-G isoforms is controversial, some original in vitro
studies indicate that the isoforms can substitute each other and have the same capacity to inhibit
cytotoxic immune cells [20,21]. Furthermore, a recent study has identified a novel landscape of HLA-G
isoforms in renal cell carcinoma patients [22]. Giving that the study reports a marked heterogeneity of
the HLA-G expression, the authors emphasize how an extensive portrait of the HLA-G isoform profile
can be favorable in development of future treatment strategies. Expression of HLA-G can be further
affected by a 14 bp insertion/deletion (ins/del) polymorphism in exon 8, the 3′-untranslated region
(UTR) of the HLA-G transcript [23]. This polymorphism influences both mRNA stability and isoform
splice patterns. Some studies point towards HLA-G mRNA isoforms including the 14 bp sequence in
the 3′UTR might be expressed at a lower level than corresponding isoforms with the 14 bp sequence
deleted [24,25].
The inhibitory role of HLA-G contributes to the idea of HLA-G being an immune checkpoint
molecule with therapeutic potential [26]. Current immunotherapeutic treatment options are already
exploiting the interactions of other immune checkpoint inhibitory receptors with their respective
ligands, such as program cell death protein 1 (PD-1) and PD-L1, and cytotoxic cell lymphocyte antigen 4
(CTLA-4) and CD80/CD86. Since these checkpoint molecules are targets for successful immunotherapy
of selected cancers only, it is essential to study the molecular role and function of HLA-G as a possible
target for new drugs.
Interestingly, HLA-G expression is rarely found on in vitro established cancer cell lines. Most likely,
the tumor microenvironment plays a vital role in the induction of HLA-G and investigation of the
specific mechanisms of differential HLA-G expression are highly important. Human interferon (IFN)-γ
plays a role in tumor immunogenicity widely known as an anti-tumor cytokine but also with a dual
role in immune evasion and tumor growth, for example through upregulation of the checkpoint
inhibitor PD-L1 and CTLA-4 [27–30]. Previous studies have shown that IFN-γ is able to induce
HLA-G expression in a number of cancer cell lines, and that the isoform profile can be regulated
by the cytokine environment [31,32]. However, cytokine induced expression of HLA-G seems to
Int. J. Mol. Sci. 2020, 21, 4307 3 of 23
be heterogeneous and highly dependent on the cell lineage. Furthermore, previous studies show
that HLA-G expression can be induced in different tumor cell lines and mesenchymal stem cells by
treatment with the demethylating agent 5-aza-2′-deoxycytidine (5-aza-dC) indicating that HLA-G
expression is regulated partly by methylation-mediated repression [33–35].
A detailed molecular investigation of HLA-G and its regulation in an in vitro breast cancer
or malignant melanoma setting will contribute to the search of mechanisms that can be exploited
to therapeutically target HLA-G-mediated immune suppression in cancer. In the present study,
we evaluated the extend of HLA class Ia and Ib expression in two breast cancer (MDA-MB-231,
MCF-7) and two malignant melanoma (FM-55M2, FM-56) cell lines focusing primarily on HLA-G.
We investigated the feasibility to manipulate expression of HLA-G by testing the effect of IFN-γ
and 5-aza-dC on HLA-G expression in the cell lines. The results indicate that methylation-mediated
repression of HLA-G can be reversed by treatment with 5-aza-dC and further induced by IFN-γ.
However, HLA-G expression was not affected by IFN-γ alone. HLA-G expression is dominated by the
presence of HLA-G1 followed by HLA-G2/4 and HLA-G3 isoforms. Furthermore, treatment with IFN-γ
or 5-aza-dC generally promoted upregulation of most HLA class Ia molecules on the surface of the
investigated cell lines, however, with some variability between the treatment conditions. Expression of
HLA-E and HLA-DR was more heterogeneous between the cell lines.
2. Results
2.1. HLA Cell Surface Expression in Breast Cancer and Malignant Melanoma Cell Lines upon
IFN-γ Stimulation
The role of IFN-γ in regulation of immunological mechanisms has been a great area of research.
In the current study, the effect of IFN-γ on surface expression of HLA-A, HLA-B, HLA-C, HLA-E,
HLA-G, and HLA-DR on MDA-MB-231, MCF-7, FM-55M2, and FM-56 cell lines was investigated by
flow cytometry. Based on previously published studies, all cell lines were treated with 24–30 ng/mL
IFN-γ and analyzed after two days of treatment [32]. Untreated JEG-3 cells, a choriocarcinoma cell line,
was included as a positive control for HLA-G expression during visualization of the flow cytometry
results. Results are presented as median fluorescence intensity (MFI) reflecting the expression level of
each marker. For every stimulated sample, there was an untreated control sample and the effect of
IFN-γ was analyzed as a direct comparison between these. It should be noted that MFI values cannot
be directly compared between cell lines as analysis was performed as separate experiments.
Based on the comparison of untreated cell lines and an isotype control, it was evident that all
investigated cell lines are HLA-G-negative, except for the HLA-G-positive JEG-3 control cell line
(Figure 1). Representative flow cytometry data for all HLA molecules for all cell lines before and after
treatment can be found in supplementary Figure S1 and S2. Unstimulated MDA-MB-231 cells expresses
HLA-A and HLA-B, some HLA-C and HLA-E and no HLA-DR, whereas unstimulated MCF-7 cells
expresses HLA-A, some HLA-E, and no HLA-B, HLA-C, or HLA-DR. The unstimulated FM-55M2 cell
line expresses HLA-A and HLA-B, very low levels of HLA-E and HLA-DR, and no HLA-C, whereas the
unstimulated FM-56 cell line expresses some HLA-B and HLA-DR and no HLA-A, HLA-C, or HLA-E.
The JEG-3 cell line expresses HLA-C, HLA-E, some HLA-A and HLA-B, and no HLA-DR. The slightly
negative MFI values observed in the results are caused by technicalities of flow cytometry making it
possible to have a negative range of fluorescence intensity, when the background signal is automatically
subtracted during acquisition of the data. All cases of negative values indicate no expression of the
respective HLA molecule. Furthermore, the baseline level of the different HLA molecules can present
with a relatively high MFI value even if there is no expression. This is caused by the adjustment of
voltages of the flow cytometer in order to obtain the best separation of cell populations.
The ability of IFN-γ to change HLA surface expression was similar for most HLA molecules
between all four treated cell lines. Treating MDA-MB-231 cells with IFN-γ for two days led to a
significant increase in surface expression of HLA-A, HLA-B, HLA-C, HLA-E, and HLA-DR (HLA-A,
p = 0.0024; HLA-B, p = 0.0165; HLA-C, p = 0.0093; HLA-E, p = 0.0200; HLA-DR, p = 0.0190) (Figure 2A).
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However, expression of HLA-G was not affected by IFN-γ. For MCF-7 cells, IFN-γ stimulated a
significant upregulation of HLA-A and HLA-B, but did not affect the expression of the other HLA
molecules (HLA- A, p < 0.0001; HLA-B, p = 0.0123) (Figure 2B). FM-55M2 cells treated with IFN-γ
for two days had a significantly higher expression of all tested HLA molecules except for HLA-G
expression (HLA-A, p = 0.0002; HLA-B, p = 0.0026; HLA-C, p < 0.0001; HLA-E, p = 0.0002; HLA-DR,
p = 0.0020) (Figure 2C). Similarly, for FM-56 cells, IFN-γ stimulated a significant upregulation of all
HLA molecules except HLA-A and HLA-G (HLA-B, p < 0.0001; HLA-C, p < 0.0001; HLA-E, p < 0.0001;
HLA-DR, p < 0.0001) (Figure 2D). Additionally, malignant melanoma cell lines were treated with IFN-γ
for four days to test the ability of IFN-γ to induce HLA-G expression after a longer incubation period.
There was no increased effect of IFN-γ upon four days of culture compared to two days (Figure S3)
and the long incubation period was therefore not tested with the remaining cell lines.
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Figure 1. Human leukocyte antigen (HLA)-G surface expression on cancer cell lines. Representative
histograms showing the expression of HLA-G on untreated cells compared to an isotype control.
MDA-MB-231, MCF-7, FM-55M2, and FM-56 cell lines are HLA-G-negative, whereas JEG-3 cells are
HLA-G-positive. Filled grey: Cells stained with isotype antibody as a negative control for HLA-G
expression; solid black: Untreated cells stained with anti-HLA-G antibody.
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Figure 2. HLA surface expression on cancer cell lines stimulated with interferon (IFN)-γ. Flow cytometry
analysis of HLA-A, HLA-B, HLA-C, HLA-G, HLA-E, and HLA-DR expression. (A) MDA-MB-231
cells treated with 30 ng/mL IFN-γ for two days. (B) MCF-7 cells treated with 24 ng/mL IFN- for
two days. (C) FM-55M2 cells treated with 30 ng/mL IFN-γ for two days. ( ) FM-56 cells treated
with 30 ng/mL IFN-γ for two days. Shown are median fluorescence intensity (MFI) with mean ± SD,
each dot represents one sample. All cell lines are HLA-G-negative and the shown MFI level of control
samples represent the background. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 (Student’s
unpaired t-test with Welch’s correction).
Int. J. Mol. Sci. 2020, 21, 4307 5 of 23
2.2. HLA Cell Surface Expression in Breast Cancer and Malignant Melanoma Cell Lines upon
Demethylation Treatment
According to previous studies, epigenetic regulation such as DNA methylation plays a role in
regulation of HLA expression. To further explore this, breast cancer and malignant melanoma cell
lines were treated with the demethylating agent 5-aza-dC and surface expression of HLA-A, HLA-B,
HLA-C, HLA-E, HLA-G, and HLA-DR was investigated by flow cytometry. Based on previously
published studies, cells were treated with two different concentrations, 10 µM and 100 µM, of 5-aza-dC
and analyzed on day three and six after treatment [33,35,36]. Representative flow cytometry data for
all cell lines before and after treatment can be found in supplementary Figure S1 and S2.
It became evident during the analysis that treatment with 5-aza-dC promoted an increase in
granularity of the cells causing an increase in autofluorescence for markers detected with fluorochromes
with low emission wavelength. This was the case for HLA-C and HLA-G conjugated to PE and BV510
fluorochromes, respectively. The inclusion of isotype controls did not compensate for the increase in
autofluorescence potentially causing a false increase in MFI for the treated samples. Furthermore,
whether the potential effect of the change in autofluorescence was equal between isotypes and specific
markers and between different samples was not transparent and isotype controls was therefore not
included in the analysis. Consequently, the interpretation of HLA-C and HLA-G that are poorly
expressed proteins must be done with caution.
The effect of 5-aza-dC on the HLA surface expression was highly variable both between the
different HLAs and the different cell lines. Results for MDA-MB-231 cells treated with 10 µM 5-aza-dC
for three days showed a significant upregulation in HLA-A, HLA-B, HLA-G, and HLA-DR surface
expression, but no change for HLA-C and HLA-E (HLA-A, p = 0.0009; HLA-B, p < 0.0001; HLA-G,
p = 0.0177; HLA-DR, p < 0.0001) (Figure 3A). When increasing the concentration to 100 µM 5-aza-dC,
MDA-MB-231 cells had an increased expression of all HLA molecules after three days of treatment
except for HLA-E expression, which seemed to decrease (HLA-A, p < 0.0001; HLA-B, p = 0.0013; HLA-C,
p = 0.0007; HLA-E, p = 0.0069; HLA-G, p < 0.0001; HLA-DR, p = 0.0006) (Figure 3A). Treating the cells
with 10 µM 5-aza-dC for six days increased the expression of all HLA molecules except for HLA-G
(HLA-A, p < 0.0001; HLA-B, p = 0.0009; HLA-C, p = 0.0353; HLA-E, p < 0.0001; HLA-DR, p = 0.0016)
(Figure 3B). Furthermore, after six days of treatment with 100 µM 5-aza-dC, surface expression of all
HLA molecules increased except for HLA-A and HLA-G expression, which did not change (HLA-B,
p = 0.0003; HLA-C, p = 0.0010; HLA-E, p < 0.0001; HLA-DR, p = 0.0043) (Figure 3B). For MCF-7
cells, we observed slightly different results. Three days of treatment with 10 µM 5-aza-dC led to
a significant upregulation of HLA-A, HLA-B, HLA-C, and HLA-G and no change for HLA-E and
HLA-DR expression (HLA-A, p = 0.0174; HLA-B, p = 0.0269; HLA-C, p = 0.0235; HLA-G, p = 0.0123)
(Figure 3E). When increasing the concentration to 100 µM 5-aza-dC, there was only a small increase
in HLA-G expression on MCF-7 cells upon three days of treatment (HLA-G, p = 0.0317) (Figure 3E).
After six days of treatment with 10 µM 5-aza-dC, surface expression increased for all HLA molecules,
now also for HLA-E, but still with no change in HLA-DR expression (HLA-A, p < 0.0001; HLA-B,
p = 0.0004; HLA-C, p < 0.0001; HLA-E, p = 0.0033; HLA-G, p < 0.0001) (Figure 3F). Furthermore,
after six days with 100 µM 5-aza-dC, results were similar to the other treatments with an increase in
HLA-A, HLA-B, HLA-C, and HLA-G surface expression, but with no change for HLA-E and HLA-DR
expression (HLA-A, p = 0.0028; HLA-B, p = 0.0198; HLA-C, p = 0.0026; HLA-G, p = 0.0065) (Figure 3F).
As we mostly observed the biggest change in HLA expression upon stimulation with 100 µM
compared to 10 µM 5-aza-dC in the breast cancer cell lines, stimulation of the malignant melanoma cell
lines was performed with only 100 µM. Treatment of FM-55M2 with 100 µM 5-aza-dC for three days
promoted a significant upregulation of HLA-B and HLA-G expression, whereas there was a decrease
in HLA-A expression and no change in HLA-C, HLA-E, and HLA-DR expression (HLA-A, p = 0.0476;
HLA-B, p = 0.0046; HLA-G, p = 0.0180) (Figure 4A). After six days of treatment, FM-55M2 cells had a
lower expression of HLA-A and HLA-C, a higher expression of HLA-E and HLA-DR, and no change
in HLA-B and HLA-G expression (HLA-A, p < 0.0001; HLA-C, p = 0.0131; HLA-E, p < 0.0001; HLA-DR,
Int. J. Mol. Sci. 2020, 21, 4307 6 of 23
p = 0.0014) (Figure 4B). For FM-56 cells, treatment with 5-aza-dC for three days led to a significant
increase in surface expression of HLA-B and HLA-G and a tendency towards higher expression of most
of the other HLA molecules (HLA-B, p = 0.0383; HLA-G, p = 0.0166) (Figure 4C). However, the cells
displayed a significantly higher expression of all HLA molecules after six days of treatment except
for HLA-DR (HLA-A, p = 0.0009; HLA-B, p = 0.0011; HLA-C, p = 0.0392; HLA-E, p < 0.0001; HLA-G,
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Figure 3. HLA surface expression on breast cancer cell lines stimulated with 5-aza-2′-deoxycytidine
(5-aza-dC). Flow cytometry analysis of HLA-A, HLA-B, HLA-C, HLA-G, HLA-E, and HLA-DR
expression. (A,B) MDA-MB-231 cells treated with either 10 µM or 100 µM 5-aza-dC for three (A) and
six days (B). (C,D) MDA-MB-231 cells treated with 10 µM 5-aza-dC and 30 ng/mL IFN-γ for three (C)
and six days (D). (E,F) MCF-7 cells treated with either 10 µM or 100 µM 5-aza-dC for three (E) and
six days (F). Shown are median fluorescence intensity (MFI) with mean ± SD, each dot represents
one sample. The shown MFI level of control samples represent a combination of background and
baseline expression. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 (Student’s unpaired t-test with
Welch’s correction).
Finally, we investigated whether a simultaneous treatment with both 5-aza-dC and IFN-γ had an
increased effect on HLA surface expression. MDA-MB-231 cells were used as a representative cell line
and treated with 10 µM 5-aza-dC and 30 ng/mL IFN-γ for three and six days. The cells displayed a
significant upregulation of expression of all HLA molecules both after three and six days of treatment
except for HLA-E expression, which decreased (HLA-A, p = 0.0007, p = 0.0011; HLA-B, p = 0.0025,
p = 0.0016; HLA-C, p = 0.0025, p < 0.0001; HLA-E, p = 0.0129, p = 0.0002; HLA-G, p < 0.0001, p < 0.0001;
HLA-DR, p = 0.0038, p = 0.0163; day three and six, respectively) (Figure 3C,D). In contrast to treating
the cells with either IFN-γ or 5-aza-dC for six days, the combined treatment led to a marked increase
in HLA-G both after three and six days of treatment.
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Figure 4. HLA surface expression on malignant melanoma cell lines stimulated with 5-aza-dC.
Flow cytometry analysis of HLA-A, HLA-B, HLA-C, HLA-G, HLA-E, and HLA-DR expression.
(A,B) FM-55M2 cells treated with 10 µM 5-aza-dC for three (A) and six days (B). (C,D) FM-56 cells
treated with 10 µM 5-aza-dC for three (C) and six days (D). Shown are median fluorescence intensity
(MFI) with mean ± SD, each dot represents one sample. The shown MFI level of control samples
represent a combination of background and baseline expression. * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001 (Student’s unpaired t-test with Welch’s correction).
2.3. HLA-G mRNA Expression in Breast Cancer and Malignant Melanoma Cell Lines
The ability of IFN-γ and 5-aza-dC to induce HLA-G surface expression was variable between
the different cell lines and to elaborate on the uncertainty about these results, induction of HLA-G
was investigated on mRNA level. Furthermore, several previous studies on HLA-G regulation focus
on mRNA expression including investigation of the soluble HLA-G isoforms. The level of HLA-G
mRNA was calculated as HLA-G copies per amount of input RNA initially used for cDNA synthesis
and subsequent digital droplet (dd)PCR. The HLA-G-positive choriocarcinoma cell line JEG-3 was
included as a control (Figure 5A). As expected, all untreated cells had no or very low levels of HLA-G
mRNA. For both breast cancer cell lines, IFN-γ treatment did not have an effect on HLA-G mRNA
levels (Figure 5B,C). The effect of IFN-γ on HLA-G mRNA expression in malignant melanoma cell
lines displayed a marked heterogeneity. The level of HLA-G increased slightly in FM-55M2 cells upon
two days of culture with IFN-γ (Figure 5D), but IFN-γ seemed to lower the HLA-G level in FM-56
cells after two days of culture (p = 0.0109) (Figure 5E). However, HLA-G levels were particularly
low in FM-55M2 and FM-56 cells upon treatment with IFN-γ questioning the effect of IFN-γ on the
transcriptional level of HLA-G.
Interestingly, treatment with 10 µM 5-aza-dC promoted a significant upregulation of HLA-G
mRNA expression in MDA-MB-231 cells after both three and six days of culture (Day 3, p = 0.0360;
Day 6, p = 0.0029) (Figure 6A). Treatment with 100 µM 5-aza-dC also seemed to induce HLA-G mRNA
expression, though not significantly (Figure 6A). Notably, HLA-G levels were higher on day six of
treatment compared to day three for corresponding samples. For MCF-7 cells, only 10 µM 5-aza-dC
induced a significant upregulation of HLA-G mRNA upon six days of culture (Day 6, p = 0.0029)
(Figure 6C). Treatment with 100 µM 5-aza-dC seemed also to increase HLA-G levels; however, there was
a variation between samples (Figure 6C).
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(B) MDA-MB-231 cells treated with 30 ng/mL IFN-γ for two days. (C) MCF-7 ls treated with
24 ng/mL IFN-γ for two days. (D) FM-55M2 cells tr ated with 30 ng/mL IFN-γ for two da . (E) FM-56
cells treated with 30 ng/mL IFN-γ for two days. Shown are mean ± SD, each dot represents one sample.
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Figure 6. HLA-G mRNA expression in stimulated breast cancer cell lines. The effect of 5-aza-dC on the
transcriptional level of HLA-G was determined by ddPCR and presented as number of HLA-G copies
per amount of RNA. (A) MDA-MB-231 cells treated with 10 µM or 100 µM 5-aza-dC for three and six
days. (B) MDA-MB-231 cells treated with a combination of 10 µM 5-aza-dC and 30 ng/mL IFN-γ for
three and six days. (C) MCF-7 cells treated with 10 µM or 100 µM 5-aza-dC for three and six days.
Shown are mean ± SD, each dot represents one sample. * p < 0.05, ** p < 0.01 (Student’s unpaired t-test
with Welch’s correction).
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With some variations in the data, there was a strong tendency towards induction of HLA-G
mRNA upon treatment with 5-aza-dC in both malignant melanoma cell lines (Figure 7A,B). Treatment
of FM-55M2 cells with 100 µM 5-aza-dC for three days promoted a significant induction of HLA-G
(p = 0.0234) (Figure 7A). Furthermore, the level of HLA-G was much higher in FM-55M2 cells compared
to FM-56 cells.
Finally, we again investigated the additive effect of simultaneous treatment with 5-aza-dC and
IFN-γ on the mRNA expression in MDA-MB-231 cells. Upon three days of treatment, the combined
effect of 5-aza-dC and IFN-γ had no significant effect on HLA-G expression compared to the control
and did not reach the level of HLA-G upon 5-aza-dC treatment alone (5-aza-dC, p = 0.0178; 5-aza-dC
vs. 5-aza-dC + IFN-γ, p = 0.0112) (Figure 6B). On day six there was a significant increase in HLA-G
expression both compared to the control and to 5-aza-dC treatment alone in agreement with the
increase in surface expression observed by flow cytometry (5-aza-dC, p = 0.0196; 5-aza-dC + IFN-γ,
p = 0.0068; 5-aza-dC vs. 5-aza-dC + IFN-γ, p = 0.0182) (Figure 6B).
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Figure 7. HLA-G mRNA expression in stimulated malignant melanoma cell lines. The effect of 5-aza-dC
on the transcriptional level of HLA-G was determined by ddPCR and presented as number of HLA-G
copies per amount of RNA. (A) FM-55M2 cells treated with 100 µM 5-aza-dC for three and six days.
(B) FM-56 cells treated with 100 µM 5-aza-dC for three and six days. Shown are mean ± SD, each dot
represents one sample. * p < 0.05 (Student’s unpaired t-test with Welch’s correction).
2.4. Verification of HLA-G Demethylation
Demethylation of the HLA-G gene upon treatment with 5-aza-dC was verified by bisulfite
sequencing. A comparison of selected CG sites within the CpG island covering exon 2-4 of the HLA-G
gene was made between MDA-MB-231 cells and JEG-3 cells (Figure 8). Untreated MDA-MB-231 cells
were methylated on investigated sites, whereas cells treated with 5-aza-dC displayed a pattern of
partly methylation on a number of CG sites corresponding to the pattern observed in HLA-G-positive
JEG-3 cells (Figure 8). The number of unmethylated CG sites was lower in treated MDA-MB-231 cells
compared with JEG-3 cells, which could represent the difference in surface expression between the two
cell lines. Hence, these results indicate that DNA demethylation was associated with the slight but
significant increase in HLA-G expression after 5-aza-dC treatment.
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2.5. Detection of HLA-G mRNA Isoforms in Breast Cancer and Malignant Melanoma Cell Lines upon
5-aza-dC Treatment
As described previously, there are seven verified HLA-G isoforms. The different isoforms might
constitute different functional forms of HLA-G, also emphasized by a ma ked heterogeneity in
isoform expressio observed within the same tumor for some cancers [22]. To further investigate
the expression of HLA-G upon 5-aza-dC tr atment, we assessed the HLA-G mRNA isoform profile.
We performed fragment analysis by capillary electrophoresis of reverse transcriptase PCR products
from MDA-MB-231, MCF-7, FM-56, and FM-55M2 cells treated with 5-aza-dC. For the malignant
melanoma cell lines, we also performed the analysis on unstimulated control cells, since ddPCR
showed low levels of HLA-G mRNA before treatment.
The presence of the 14 bp 3′ UTR insertion polymorphism can facilitate further splicing of 92 bp
from the 3′UTR from all seven HLA-G isoforms, thus affecting analysis of the isoform landscape.
In order to detect specific splice variants of the isoforms in the fragment analysis, the presence of the
14 bp polymorphism in all cell lines was investigated by TaqMan assay (Table 1). Breast cancer cell
lines MDA-MB-231 and MCF-7 are both homozygous for the 14 bp deletion. The FM-56 and JEG-3
cell lines are homozygous for the 14 bp insertion while the FM-55M2 cell line are heterozygous with
respect to the 14 bp sequence polymorphism.
As described, the 14 bp polymorphism results in isoforms of different lengths depending on
splicing of the 92 bp but for simplicity, we refer to the isoforms as G1-G7 for all cell lines. We were able
to identify peaks in the electropherograms corresponding to the predicted sizes of HLA-G1 (894 bp),
G2/4 (619 bp), -G3 (345 bp), and -G5 (1017 bp). Representative electropherograms are shown in Figure 9,
as well as an electropherogram based on mRNA from the JEG-3 cell line that expresses high levels
of HLA-G. In the MDA-MB-231 and FM-55M2 cells, we detected the highest signal from HLA-G1
followed by HLA-G2/4 and HLA-G3. In the samples with the highest signal, we were also able to detect
a peak corresponding to HLA-G5. For FM-55M2 cells, we detected a peak corresponding to HLA-G1
both with and without the 14 bp insertion as well as small peaks for HLA-G2/4 and -G3 with the 14 bp
insertion. In FM-56 cells, we detected only HLA-G1. For MCF-7 cells and non-treated FM-55M2 and
FM56 cells, we failed to detect any peaks due to low signal intensity. For the HLA-G-positive cell line
JEG-3, we confirmed the presence of HLA-G1-5 isoforms (Figure 9). As a result of the presence of the
14 bp insertion, we also detected a ∆92 bp splice variant for HLA-G1 and HLA-G2/4.
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Table 1. HLA-G 14 bp insertion/deletion (ins/del) 3′UTR polymorphism in the cancer cell lines.






The signal intensity was generally low for breast cancer and malignant melanoma cell lines
compared to JEG-3 cells and thus expression levels of the low-expressed HLA-G isoforms presumably
fell below the limit of detection preventing a semi-quantitative analysis of the distribution of HLA-G
isoforms in the samples. The quality of the original RNA purified from treated cells was checked by
automated electrophoresis and was consistently high for all samples, ruling out that poor RNA quality
was the cause of missing signals in the fragment analysis (data not shown).
3. Discussion
HLA-G is a well-studied molecule and information regarding its regulatory role in cancer is
accumulating. To explore how cancer cell lines regulate HLA expression and whether HLA-G
expression can be induced by the cytokine IFN-γ and the demethylating agent 5-aza-dC, we treated
selected malignant melanoma and breast cancer cell lines with these two compounds, both individually
and combined, and measured the effect on mRNA and cell surface expression levels. Expression of
HLA-A, HLA-B, HLA-C, and HLA-E were included in this study in order to broaden the knowledge
on how IFN-γ and 5-aza-dC affect both classical and non-classical HLA molecules giving that a
concomitant deregulation of HLA class Ia and Ib molecules is associated with immune evasion in
cancer [37]. Finally, the HLA class II molecule HLA-DR was included. HLA-DR is less studied
with respect to cancer but increasing evidence suggests that HLA-DR might have a predictive role
for malignant melanoma. The choice of stimulating cancer cell lines with both IFN-γ and 5-aza-dC
addresses two different molecular mechanisms for regulation of HLA gene expression. A summary of
the findings can be found in Table 2.
In the present study, IFN-γ treatment had no effect on HLA-G mRNA level or protein expression
in any of the cell lines. The HLA-G mRNA seemed to decrease in FM-56 cells, but a decrease in
HLA-G might be attributed to the uncertainty in the noticeably low mRNA level detected with ddPCR
analysis. With some variability between cell lines, IFN-γ mainly promoted an upregulation of the other
investigated HLA molecules. The ability of IFN-γ to induce HLA class Ia antigen expression in cancer
cells has been observed previously. An early study by Jabrane-Ferrat et al. detected HLA class Ia and
HLA-DR surface expression on MDA-MB-231 and MCF-7 breast cancer cell lines that were increased by
IFN-γ treatment [38]. In the present study, a similar increase was observed for only MDA-MB-231 cells.
A study by Rodríguez et al. found that out of 57 cell lines, only two (ESTDAB-004 and ESTDAB-159) did
not increase mRNA or surface expression of HLA-ABC upon treatment with IFN-γ [39]. The absence
of IFN-γ-mediated expression of HLA-ABC in one of the cell lines was presumably due to epigenetic
blocking of the IFN-γ response element IRF-1, since expression could be induced by a concomitant
treatment with both IFN-γ and the demethylation agent 5-aza-dC.
When it comes to HLA-G surface expression, HLA-G expression is rarely detected on in vitro
established cancer cell lines making it challenging to study the molecular function of HLA-G.
A comprehensive study by Polakova and Russ on 75 different cancer cell lines including melanoma
and breast cancer (e.g., MDA-MB-231 and MCF-7) imply that under normal culture conditions the cell
surface expression of HLA-G is absent in most cancer cell lines across different origin [40]. Similarly,
a study by Frumento et al. of 45 melanoma cell lines showed no evidence of neither mRNA or protein
HLA-G expression, nor that it could be induced by IFN-γ treatment [41]. The four investigated cell lines
in the present study is also HLA-G-negative. Surprisingly, there is a discrepancy between the frequent
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expression of HLA-G in tumor lesions and the lack of HLA-G expression in most cancer cell lines.
This reflect a lack of selection pressure for HLA-G expression for cells that are cultured in vitro. This is
supported by a study by Rouas-Freiss et al. showing that the Fon melanoma cell line loses cell-surface
expression of HLA-G1 upon long-term culture [42], which is also seen in previous studies on renal
carcinoma cell lines [43] and ovarian carcinoma cell lines [44]. Furthermore, Rouas-Freiss et al. showed
that treatment with IFN-γ and 5-aza-dC demethylating agent increased HLA-G1 cell-surface expression
on HLA-G-positive cells. However, HLA-G1 re-expression was not induced in HLA-G-negative cells
upon treatment. The concentration of IFN-γ in patients are often lower in both peripheral blood and
in the tumor microenvironment than the concentration used in the present study that was chosen
with the aim to boost HLA-G expression [45,46]. As we do not observe an effect of IFN-γ on the
expression of HLA-G it is unlikely that IFN-γ could be an independent inducer of HLA-G in the tumor
microenvironment at lower concentrations.
Table 2. Summary of findings.
Cell Line Condition HLA-A HLA-B HLA-C HLA-E HLA-G * HLA-DR
MDA-MB-231
Untreated ** + + (+) *** (+) − −
IFN-γ ↑ ↑ ↑ ↑ − ↑
5-Aza-dC
10 µM, day 3 ↑ ↑ − − ↑ ↑
10 µM, day 6 ↑ ↑ ↑ ↑ - ↑
100 µM, day 3 ↑ ↑ ↑ ↓ ↑ ↑
100 µM, day 6 − ↑ ↑ ↑ − ↑
MCF-7
Untreated + − − (+) − −
IFN-γ ↑ ↑ − − − −
5-Aza-dC
10 µM, day 3 ↑ ↑ ↑ - ↑ −
10 µM, day 6 ↑ ↑ ↑ ↑ ↑ −
100 µM, day 3 − − − − ↑ −
100 µM, day 6 ↑ ↑ ↑ - ↑ -
FM-55M2
Untreated + + − (+) − (+)
IFN-γ ↑ ↑ ↑ ↑ − ↑
5-Aza-dC
100 µM, day 3 ↓ ↑ - - ↑ −
100 µM, day 6 ↓ − ↓ ↑ − ↑
FM-56
Untreated − (+) − − − +
IFN-γ − ↑ ↑ ↑ − ↑
5-Aza-dC
100 µM, day 3 − ↑ − − ↑ −
100 µM, day 6 ↑ ↑ ↑ ↑ ↑ −
JEG-3 Untreated (+) (+) + + + −
* Combined results for HLA-G surface expression and mRNA expression. ** Expression based upon
comparison between the specific marker and isotype control. *** Parentheses indicate possible low expression
or expression difficult to interpret because of differences in the MFI distributions of isotype and specific marker
antibody, respectively.
Whereas we did not see an upregulation of HLA-G upon IFN-γ stimulation, we did see a clear
upregulation of HLA-G upon treatment with a combination of IFN-γ and 5-aza-dC. These results
indicate that IFN-γmight be involved in maintaining HLA-G expression rather than inducing expression.
This is also observed in one of our previous studies with a focus on reproductive immunology [32].
The analysis of HLA-DR expression upon IFN-γ treatment aids to the emerging interest in the
role of HLA-DR during cancer immune surveillance. When stimulating the melanoma cell lines
with IFN-γ, expression of HLA-DR significantly increased, which was consistent with observations
of other studies [47,48]. Although expression of HLA class II molecules is usually restricted to
Int. J. Mol. Sci. 2020, 21, 4307 14 of 23
antigen- presenting cells, studies show that almost 50% of melanomas constitutively express HLA
class II, and that HLA-DR expression in malignant melanoma correlates with increased motility,
migration, and expression of adhesion molecules [47]. Thus, expression of HLA-DR in malignant
melanoma correlates with a worse prognosis. On the other hand, HLA-DR expression is associated
with therapeutic response in a cohort of anti-PD1 treated patients suggesting that HLA-DR could be a
possible positive predictor of anti PD-1 immunotherapy [48].
Lack of HLA-G expression seems to be independent of repression of other HLA class I and II
molecules as expression of these is observed even when HLA-G is absent. The difference in expression
of HLA class Ia molecules and HLA-G might be attributed to differences in the regulatory elements
upstream from the translation start site of each HLA gene. Although many variable sites in the
promoter region of HLA genes are conserved, variability in the transcription factor target sites most
likely influences the differential regulation. The IFN-stimulated response element (ISRE) located in the
proximal promoter region of HLA class I genes displays locus-specific nucleotide variation between
the different HLAs leading to differences in IFN-γ-induced expression levels of HLA class I genes [49].
The ISRE sequence of the HLA-G gene is the most divergent compared to the ISRE consensus sequence
preventing binding of interferon regulatory factors and raising the issue of whether the HLA-G ISRE is
fully functional [50]. The HLA-G gene also contains other regulatory elements, which are not functional
(reviewed in [50]). Combined with ISRE is the Enhancer A (EnhA) module and next to it a SXY module.
The NFkB responsive element of EnhA is more efficient for HLA class Ia than for class Ib genes [51].
The SXY module is crucial for CIITA; however, divergence of the X2 and Y elements prevents CIITA
transactivation of HLA-G [51,52]. Most likely, several mechanisms play a role in regulation of HLA
protein expression in different cases of cancer. Differences in IFN-γ-mediated inducibility of HLA
molecules between cancer cell lines may reflect differences in the cytokine reactivity and nature of the
original tumor cells. Understanding the mechanisms by which tumors react to IFN-γ signaling will
contribute to therapeutic decision making and help predicting response to immunotherapy, as it might
represent a potential mechanism of resistance to therapy. In relation to this, the differential regulation
of HLA class I molecules must be taken into consideration and might show as an advantage when
choosing a treatment strategy.
The first evidence that DNA hypermethylation is used by cancer cells to switch off HLA class
I genes was provided by Serrano et al. in 2001, where treatment with 10 µM 5-aza-dC for 15 days
restored HLA-ABC expression on the otherwise HLA-ABC-negative melanoma cell line MSR3-mel [53].
Upon demethylation, HLA-ABC expression could be further induced by IFN-γ treatment. The ability
to induce HLA-ABC molecules by exposure to 5-aza-dC was furthermore seen for the melanoma cell
line Mel 275, also leading to induced recognition by cytotoxic T lymphocytes [54]. In the present study,
we also observed a significant upregulation of HLA class Ia molecules after treatment with 5-aza-dC
on all cell lines that normally expressed HLA class Ia. For HLA-E, the results were more diverse.
Expression of HLA-DR was not affected by 5-aza-dC treatment in MCF-7 and FM-56 cells, but was
upregulated upon all treatment conditions in MDA-MB-231 cells and after six days of treatment
in FM-55M2 cells. Finally, there was a tendency towards higher expression of HLA-G in all cell
lines keeping in mind the uncertainty with the cell surface expression of HLA-G measured by flow
cytometry. For future studies, an alternative analysis methodology that overcome the prerequisite of
flow cytometry to analyze only cells with same size and granularity is recommended to fully elaborate
on the ability of 5-aza-dC to induce HLA-G surface expression. Nevertheless, the verification of DNA
demethylation by bisulfite sequencing and the demonstrated increase in HLA-G mRNA upon treatment
indicated that HLA-G transcription is partly regulated by DNA methylation. Previous studies have
also revealed that HLA-G gene transcription is inhibited by DNA methylation. A previous study has
proven an induction of HLA-G in MCF-7 cells upon treatment with 5-aza-dC and IFN-γ [55]. However,
this study was unable to detect cell surface expression of HLA-G by flow cytometry. Another study
by Moreau et al. showed that treatment with 1, 10, and 100 µM 5-aza-dC for three days induced
expression of HLA-G in selected cancer cell lines from embryonal carcinoma, leukemia, lymphomas,
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and melanoma [33]. Bisulfite sequencing of the 450 bp promoter region upstream from the transcription
start site of HLA-G in some of the same cell lines showed that the degree of CpG methylation correlated
with expression [56]. Similar results have been observed for the melanoma cell line OCM-1A where
bisulfite sequencing revealed methylation of 87% of CpG sites in the promoter region of HLA-G before
treatment compared to only 2% after treatment [57]. Furthermore, the level of methylation in the
HLA-G promoter region seem to differ between normal ovarian surface epithelium and ovarian tumors,
though not associated with the expression level [58]. Interestingly, this study showed that CpG sites
related to a hypoxia response element (HRE) remained methylated even upon 5-aza-dC treatment
of an ovarian cancer cell line suggesting a strong selection against loss of methylation in this region.
Investigation of the HLA-G promoter region and part of the CpG island in colorectal cancer cell lines
and choriocarcinoma cell lines have further showed a discrepancy between methylation level and
HLA-G expression [59,60]. Similar results is observed in a database search on invasive breast carcinoma
using the Wanderer tool, which visualizes gene expression and DNA methylation profiles obtained
from the TCGA research network [61]. Breast tumor tissue seem to display a higher percentage of
methylation at selected CG sites in the HLA-G gene compared with normal breast tissue; however,
there is no significant difference in HLA-G expression. Combined, these findings suggest that DNA
methylation is not the sole mechanism regulating HLA-G expression, especially in human tumors,
where heterogeneous HLA-G expression can represent the complex interaction between cancer cells
and factors in the tumor microenvironment that are not present in vitro.
Fragment analysis of cells treated with 5-aza-dC revealed that the predominant HLA-G isoform
was HLA-G1, followed by HLA-G2/4 and HLA-G3. The HLA-G5 isoform was also observed for the
MDA-MB-231 cells. However, there was a low signal intensity in the analysis possibly hiding the
presence of other isoforms. This is emphasized by the high signal and clear presence of HLA-G1-5 in the
HLA-G-positive JEG-3 cell line. The low signal intensity was presumably due to low mRNA levels in
general, in spite of 5-aza-dC-mediated induction of low levels of HLA-G in otherwise HLA-G-negative
cell lines. Furthermore, the discrepancy between the HLA-G mRNA levels detected by ddPCR and
the low signal obtained by fragment analysis indicate that the latter technique is limited by assay
sensitivity. To fully elucidate on the HLA-G isoform profile in the cancer cell lines upon 5-aza-dC
treatment a more sensitive method such as RNA sequencing is required. When comparing the isoform
profile and the protein level detected by flow cytometry, there is a clear correlation between the results.
The HLA-G antibody used detects HLA-G1 and HLA-G5 isoforms and with all cell lines predominantly
expressing HLA-G1, the surface expression level reflects the majority of the total HLA-G expression
level. However, the surface expression of HLA-G is presumably higher than detected due to expression
of HLA-G2-4 isoforms, which are not detected by the antibody used. The level of surface expression
might especially be higher for JEG-3 cells that present with a relatively higher level of HLA-G1-5
isoforms compared to the other cell lines.
Altogether, our results support that reversal of methylation-mediated repression of HLA-G is a
co-acting mechanism by which tumor cells can take advantage of in order to avoid immune recognition.
Demethylation is a common mechanism exploited by cancer cells to induce gene transcription and
can explain the difference between HLA-G expression in vivo and in vitro when there is no selection
pressure from the tumor microenvironment. A similar model has been proposed before for melanoma
cells. Expression of HLA-G in melanocytes can be induced during malignant transformation mediated
by stress and epigenetic mechanisms otherwise employed by the cancer cells to facilitate the oncogenic
transformation. However, adaptation to in vitro culture conditions might lead to methylation due
to the lack of stress signals from the tumor microenvironment [62]. Other possible factors involved
in signaling within the tumor microenvironment for breast cancer include the hormone receptor
status. There seem to be an association between estrogen receptor (ER) status and HLA expression.
The frequency of HLA class II-positive tumor cells are lower in ER positive breast carcinomas compared
to ER-negative tumors [63]. Furthermore, ER signaling differentially modulates IFN-γ-mediated HLA
class II induction in breast cancer cell lines as estradiol attenuates HLA-DR expression in ER-positive
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cells [64]. Interestingly, this correlates with the expression of HLA-DR observed in the present study.
MDA-MB-231 cells are estrogen receptor-negative and display a marked induction in HLA-DR surface
expression upon treatment. On the other hand, MCF-7 cells are estrogen receptor-positive with no
expression of HLA-DR before or after treatment. Other cytokines, such as IL-4 also seems to be related
to the hormone receptor status and to clinical outcome [65]. The extensive cytokine profile in the tumor
microenvironment plays an important role in cancer progression. A previous study on MDA-MB-231
and MCF-7 cell lines show that IL-6 and IL-10 are associated with good prognosis in breast cancer [66].
Furthermore, distinct patterns of cytokines, including expression of IFN-γ, IL-4, and IL-10, have been
observed in specific breast cancer groups compared to a healthy population [67]. Whether these
cytokines might be involved in epigenetic changes such as DNA methylation is an interesting question
to address in future studies.
It could be speculated that the HLA expression profile is reflected by the nature of the original
cancer giving rise to the cancer cell lines. Both breast cancer cell lines originate from pleural effusion
and display similar expression profiles for most HLA molecules except HLA-DR. Treatment with
IFN-γ and 5-aza-dC seems to be more potent inducers of HLA surface expression on MDA-MB-231
cells compared to the MCF-7 cells. Whereas the FM-55M2 cells originate from lymph node metastasis,
FM-56 cells originate from a primary tumor. Despite the nature of the cancer, the HLA expression
profile are similar for the two cell lines except for HLA-A expression which seems to be low or absent
on unstimulated FM-56 cells. Furthermore, the effect of IFN-γ and 5-aza-dC on HLA surface expression
is similar for most HLAs on both cell lines. The HLA-G isoform profile is also similar for all four
cell lines predominantly expressing HLA-G1. Consequently, there is no indication that the nature
of the tumor is related to the expression of HLA molecules in the in vitro setting investigated in the
present study.
A broader understanding of the mechanism by which HLA-G expression is regulated is essential
in the development of immune checkpoint inhibitors targeted at HLA-G. The expression of HLA-G in
tumor lesions should also be taken into consideration in the design of therapeutic strategies. Assuming
that HLA-G is associated with poor clinical outcome the aim of therapeutic interventions should
be to prevent a possible induction of its expression in tumors negative for HLA-G. The present
study demonstrate two different approaches to manipulate HLA expression in an in vitro breast
cancer and malignant melanoma setting and support a role for DNA methylation in regulation of
HLA-G expression. The results presented here can pave the way for further research related to
methylation-mediated regulation of HLA class I and class II expression. Furthermore, future studies
investigating combinations of different cytokines present in the tumor microenvironment will be
essential for the understanding of regulatory factors promoting epigenetic changes that affect HLA
expression in primary tumors.
4. Materials and Methods
4.1. Cells and Culture Conditions
The current study was performed on four different cell lines from two different cancers:
Human breast cancer cell lines MDA-MB-231 (pleural effusion) and MCF-7 (pleural effusion),
and human malignant melanoma cell lines FM-56 (primary melanoma) and FM-55M2 (lymph node
metastasis), which was kindly provided by Prof. Mads Hald Andersen, Herlev Hospital, Denmark.
Human choriocarcinoma cell line JEG-3 (ATCC, Manassas, VA, USA, #HTB-36) was used as a
HLA-G-positive control cell line. JEG-3 and MCF-7 cells were cultured in Eagle’s Minimum Essential
Medium (EMEM, ATCC®-30-2003TM) and MDA-MB-231, FM-56, and FM-55M2 cells were cultured in
Roswell Park Memorial Institute 1640 medium (RPMI, ThermoFisher, Waltham, MA, USA, #61870-010).
Culture medium was supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS; Sigma-Aldrich,
St. Louis, MO, USA, #F9665). All cells were cultured at 37 ◦C and 5% CO2 and sub-cultured when
they reached 75–80% confluency. For cell passaging and cell harvest, the cells were gently washed
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in phosphate-buffered saline (PBS, ThermoFisher, Waltham, MA, USA, #14190250) and trypsinized
using 0.25% EDTA-Trypsin (ThermoFisher, Waltham, MA, USA, #25200056). Cells were pelleted by
centrifugation at 300 g for 10 min at room temperature, resuspended in fresh culture medium and
transferred to new culture flasks. Cell lines were cryopreserved in FBS supplemented with 10%
dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO, USA; #D2650).
4.2. Cell Treatments
One day prior to treatment, 100,000 cells per well were seeded in triplicates in 6-well plates
(Fischer Scientific, Waltham, MA, USA, #140675). On the day of treatment, medium was replaced with
fresh medium containing the specified stimulation agents. Cells were treated with either 30 ng/mL
human IFN-γ (Miltenyi, Bergisch Gladbach, Germany, #130-096-872), except for MCF-7 cells that were
treated with 24 ng/mL IFN-γ, diluted in deionized water containing 0.1% bovine serum albumin
(BSA; Sigma-Aldrich, St. Louis, MO, USA, #A7030) or 10 µM and 100 µM 5-aza-dC (Calbiochem,
Sigma-Aldrich, St. Louis, MO, USA, #189826-10MG) diluted in DMSO or both 30 ng/mL human IFN-γ
and 10 µM 5-aza-dC. Stimulation with deionized water containing 0.1% BSA or DMSO added in the
same concentrations as for the respective assays was used as control. All assays were performed in
the same cell passage. Cells treated with IFN-γ were incubated for two days and cells treated with
5-aza-dC were incubated for three and six days until analyzed by flow cytometry and harvested for
DNA and RNA purification. Cells treated with 5-aza-dC for 6 days had 2 mL medium removed and
replaced with fresh medium without 5-aza-dC on day 3.
4.3. Flow Cytometry
Untreated and treated cells were harvested and analyzed by flow cytometry. All washing and
staining of the cells were performed with BD FACSFlowTM buffer (BD BioSciences, Franklin Lakes,
NJ, USA) or PBS supplemented with 1–10% FBS. To discriminate live and dead cells, LIVE/DEAD
Fixable Violet Dead Cell Stain Kit (Life Technologies, Carlsbad, CA, USA, #L34955) was used according
to the manufacturer’s protocol. Afterwards, cells were washed once, pelleted by centrifugation
and resuspended in 100 µL buffer. Cells were stained for 15 min with antibodies PE anti-human
HLA-G (clone: 87G;Exbio, Prague, CZ, #1P-437-C100), PerCP-Cy5.5 anti-human HLA-A2 (clone: BB7.2;
Biolegend, San Diego, CA, USA, #343316), PE-Cy7 anti-human HLA-E (clone: 3D12; Biolegend,
San Diego, CA, USA, #342608), APC anti-human HLA Class I Bw6 (clone: REA143; Miltenyi, Bergisch
Gladbach, Germany, #130-099-845), APC-eFluor 780 anti-human HLA-DR (clone: LN3; Thermofisher,
Waltham, MA, USA, #47-9956-42) and BV510 anti-human HLA-C (clone: DT9; BD Biosciences, Franklin
Lakes, NJ, USA #747597). The cells were washed once in 3 mL buffer, resuspended in 200 µL buffer
and immediately analyzed on a FACSCanto II flow cytometer (BD BioSciences, Franklin Lakes, NJ,
USA) using FACS Diva Software (BD BioSciences, Franklin Lakes, NJ, USA, version 8.01). For each
sample, 50,000 events were recorded. Further analysis was performed using FACS Diva Software and
FlowJoTM Software (BD Biosciences, Franklin Lakes, NJ, USA, version 10).
4.4. DNA and RNA Extraction and cDNA Synthesis
For DNA and RNA purification, cell pellets were harvested as described above. The harvested
cells were quickly stored as a dry pellet at −80 ◦C. Genomic DNA and total RNA were extracted
simultaneously using the AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany, #80204) following
the manufacturer’s protocol for Simultaneous Purification of Genomic DNA and Total RNA from Animal
Cells. Cells were lysed and homogenized by vortexing. Purification of RNA alone was performed
using the RNeasy® Micro Kit (Qiagen, Hilden, Germany, #74004) following manufacturer’s protocol
for Purification of Total RNA from Animal and Human cells. DNA was eluted in 50 µL elution buffer
supplied with the kit and RNA was eluted in 30 µL RNase-free water supplied with the kits. DNA and
RNA concentrations were measured using DropSense 96 (Unchained Labs, Pleasanton, CA, USA).
The DNA was stored at −20 ◦C until use. The total RNA was stored at −80 ◦C until use. Quality of
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the purified RNA was assessed from a selection of the samples by automated electrophoresis using
the Agilent 2100 Bioanalyzer system (Agilent, Santa Clara, CA, USA) and the Agilent RNA 6000 Pico
Kit (Agilent, Santa Clara, CA, USA, #5067-1513) following manufacturer’s instructions. First-strand
cDNA synthesis with SuperScript® VILO™ cDNA synthesis kit (Invitrogen, ThermoFisher, Waltham,
MA, USA, #11754050) was performed using maximum 2.5 µg of the extracted RNA and following the
manufacturer’s instructions, and cDNA was stored at −20 ◦C until further use.
4.5. Digital Droplet PCR
Droplet digital (dd)PCR was performed using the QX100 Droplet Digital PCR system (BioRad,
Hercules, CA, USA) as previously described [32]. In short, cDNA equivalent to 70–250 ng of total RNA,
10 µL 2x ddPCRTM Supermix for Probes (Bio-Rad, Hercules, CA, USA, #186-3024), 10 µM of HLA-G
forward primer (5′-AGC AGT CTT CCC TGC CCA CC-3′) and HLA-G reverse primer (5′-AGC TCC
CTC CTT TTC AAT CTG AGC TC-3′), 4 µM probe (5′-FAM-CCT TGC AGC TGT AGT CAC TGG
AGC TGC GGT CG-BHQ-1-3′) and nuclease-free water in a total volume of 20 µL were used for each
reaction. Cycling conditions were: 95 ◦C for 10 min, followed by 40 cycles of 95 ◦C for 15 s, 62 ◦C for
1 min, 72 ◦C for 1 min, finally ending reaction at 98 ◦C for 10 min and hold at 4 ◦C. Specific amplicons
were confirmed by electrophoresis on a 2% agarose gel. Results were analyzed using the QuantaSoft®
software version 1.3.2.0 (Bio-Rad, Hercules, CA, USA).
4.6. PCR and Fragment Analysis
PCR was performed with 90–320 ng cDNA, using 13.5 µL of GoTaq® Hot Start Master Mix
(Promega, Madison, WIS, USA, #M5133), 1 µM of HLA-G1-6 forward primer (5′-CAC AGA CTG ACA
GAA TGA ACC TGC A-3′) and HLA-G1-6 reverse primer (5′-FAM-GGA AGG AAT GCA GTT CAG
CAT GA-3′), and nuclease-free water in a total volume of 25 µL for each reaction.. The PCR was run
under following conditions: 95 ◦C for 2 min, 29 cycles of 95 ◦C for 30 s, 62 ◦C for 2 min and 72 ◦C
for 2 min, followed by 72 ◦C for 10 min and ending with hold at 4 ◦C. The PCR product was used
directly for fragment analysis or stored overnight in the dark at 4 ◦C. For fragment analysis, 10 µL
of nuclease-free water and 0.5 µL of GeneScanTM 1200 LIZTM dye size standard (Life Technologies,
Carlsbad, CA, USA, #4379950) were added to each well containing 2 µL of the PCR product and
subsequently denatured at 95 ◦C for 3 min. followed by incubation on ice for 2 min. Fragment analysis
on the ABI3500 Genetic Analyzer (Applied Biosystems, Waltham, MA, USA) was performed after the
cooling. The PCR fragment lengths were analyzed using the GeneMarker® software (SoftGenetics, PA,
USA). Analysis on 10% of randomly chosen samples were performed in duplicates.
4.7. Genotyping of the HLA-G 14 bp Ins/Del Polymorphism
Genotyping of the HLA-G 14 bp ins/del polymorphism in JEG-3, FM-55M2, FM-56, MDA-MB-231
and MCF-7 cells was performed by TaqMan assay as previously described [68]. Briefly, 200–250 ng
DNA, 10 µL 2x LightCycler 480 mastermix for probes (Roche Diagnostics, Basel, CH), 0.5 µM of
HLAG14 forward primer (5′-GTG ATG GGC TGT TTA AAG TGT CAC C-3′) and HLAG14 reverse
primer (5′-GGA AGG AAT GCA GTT CAG CAT GA-3′), 0.07 µM HLAG14 FAM probe (5′-FAM-CAA
GAT TTG TTC ATG CCT TCC C-BHQ-1-3′), 0.3 µM HLAGdel Cy5 probe (5′Cy5-GAG TGG CAA
GTC CCT TTG TG-BHQ-2-3′) and nuclease-free water in a total volume of 20 µL was used for each
reaction. The real-time TaqMan PCR assay was performed using a LightCycler 480 instrument (Roche
Diagnostics, Basel, CH). Cycling conditions were: 95 ◦C for 10 min, followed by 50 cycles of 95 ◦C for
10 s, 60 ◦C for 50 s, 72 ◦C for 1 s finally ending reaction by hold at 4 ◦C for 10 s.
4.8. Bisulfite Sequencing
Bisulfite conversion of 300–350 ng purified genomic DNA was carried out using the EZ
DNA Methylation-Lightning Kit (Zymo Research, Nordic Biosite, Täby, SE, #D5031) following
the manufacturer’s protocol. The HLA-G sequence was obtained from NCBI Reference Sequence
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NG_029039.1 and prediction of the 5′ CpG island from the UCSC Genome Browser. Target-specific
bisulfite sequencing PCR primers with M13 tags were designed in three pairs overlapping and covering
the CpG island. Pair F1R2: forward 5′-TTA GGT GAT AGG TTT TTA GAG AAG TTA ATT-3′, reverse
5′-ATT CCA TAT CTC CTC TTC CCA ATA-3′; pair F2R3: forward 5′-TTT AGG TTT TTA TTT TAT GAG
GTA TTT TAG-3′, reverse 5′-ACC AAT CAT CCA CTA AAA AAT ATA AAA AC-3′; pair F3R1: 5′-AGA
TTT TTT ATT TGG GAG AAT TTT AAG G-3′, reverse 5′-ATA TTA ATC CCA TTT TCC TCC TCT
CC-3′. Specificity of bisulfite-specific primers were confirmed using the online tool BiSearch [69,70].
In brief, the PCR was performed with 2 µL bisulfite converted DNA, 5 µL 2x KAPA HiFi HotStart
Uracil+ ReadyMix (Roche Diagnostics, Basel, CH, #7959052001) and 6 µM of each primer in a total
volume of 10 µL for each reaction. A touchdown PCR for bisulfite converted DNA was run under
the following conditions: 95 ◦C for 5 min., 17 cycles of: 95 ◦C for 20 s, 65 ◦C for 20 s and 72 ◦C for
45 s, followed by 30 cycles of: 95 ◦C for 20 s, 50 ◦C for 20 s and 72 ◦C for 45 s, finally ending reaction
at 72 ◦C for 5 min and hold at 4 ◦C. PCR products were purified using AMPureXP on Biomek 4000
(both from Beckman Coulter, Brea, CA, USA). Sanger sequencing was performed using the BigDyeTM
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Waltham, MA, USA, #4337455), 2 µL PCR
product, 4 µM sequencing primer and nuclease-free water in a total volume of 10 µL for each reaction.
The sequencing reaction was carried out at the following conditions: 96 ◦C for 1 min, 35 cycles of 96 ◦C
for 30 s, 50 ◦C for 15 s, 60 ◦C for 4 min, finally ending reaction by hold at 4 ◦C. The products were
purified using CleanSeq (Beckman Coulter, Brea, CA, USA) on Biomek 4000. Bidirectional Sanger
sequencing was performed on ABI3500 Genetic Analyzer (Applied Biosystems, Waltham, MA, USA).
The results were analyzed using Mutation Surveyor (SoftGenetics, PA, USA).
4.9. Statistical Analysis
If not otherwise stated, experiments were performed in triplicates. Figures and statistical analysis
were executed using GraphPad Prism® software (GraphPad, San Diego, CA, USA). p-values < 0.05
were considered statistically significant, and marked in the figures accordingly: * p < 0.05; ** p < 0.01;
*** p < 0.001 and **** p < 0.0001. Student’s unpaired t-test with Welch’s correction was used for
comparison of IFN-γ and 5-aza-dC treated samples to their respective controls for flow cytometry data
and ddPCR results.
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S3: HLA surface expression on malignant melanoma cells stimulated with IFN-γ.
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